Optimistic forecasts from U.S. memory giant Micron fueled gains on the Nasdaq, while solid earnings strengthened confidence that the AI trend remains robust. Analysts at Cantor Fitzgerald and Deutsche Bank raised their price target for Micron (MU.US) to $200 per share, citing AI infrastructure as the key driver. Goldman Sachs set its target much more defensivly at $145 per share (more than 10% below Micron share price). Additionally, shares of Chinese tech giant Alibaba rose after forecasts of AI infrastructure spending were lifted above the initially estimated $50 billion. This reinforces the market’s belief that Chinese companies are “catching up” with their U.S. counterparts.
Start investing today or test a free demo
Create account Try a demo Download mobile app Download mobile appSource: xStation5
Micron Technology presented forecasts far exceeding market expectations – the company projects $12.5 billion in Q1 revenue, compared with analysts’ estimates of $11.9 billion. Earnings per share are expected at $3.75, well above the consensus of $3.05.
- Growth is being driven by rising demand for artificial intelligence solutions, particularly HBM (High Bandwidth Memory), which is essential for powering AI chips and systems.
- CEO Sanjay Mehrotra emphasized that Micron is entering fiscal 2026 “with strong momentum” and the “most competitive portfolio in its history.” It remains the only memory manufacturer headquartered in the U.S.
- In Q4 (ended August 28), the company reported a 46% revenue increase to $11.3 billion, with EPS of $3.03, surpassing expectations.
The stock gained over 3% after the results and has nearly doubled since the start of the year, significantly outperforming peers thanks to the AI boom and growing demand from the data center sector, which now accounts for more than half of the group’s revenue. The company is likely to reach a new record above $170 per share today.
Source: xStation5
European ADRs of Alibaba are up nearly 8% today, trading at their highest levels since autumn 2021.
Source: xStation5
The material on this page does not constitute as financial advice and does not take into account your level of understanding, investment objectives, financial situation or any other particular needs.
All the information provided, including opinions, market research, mathematical results and technical analyses published on the website or transmitted to you by other means is provided for information purposes only and should in no event be interpreted as an offer of, or solicitation for, a transaction in any financial instrument, nor should the information provided be construed as advice of legal or fiscal nature.
Any investment decisions you make shall be based exclusively on your level of understanding, investment objectives, financial situation or any other particular needs. Any decision to act on information published on the website or transmitted to you by other means is entirely at your own risk. You are solely responsible for such decisions.
If you are in doubt or are not sure that you understand a particular product, instrument, service, or transaction, you should seek professional or legal advice before trading.
Investing in OTC Derivatives carries a high degree of risk, as they are leveraged based products and often small movements in the market could lead to much larger movements in the value of your investment and this could work against you or for you. Please ensure that you fully understand the risks involved, taking into account your investments objectives and level of experience, before trading, and if necessary, seek independent advice.
